Ann: GENERAL: FPH: FPH Introduces New Range of Products for...

• Release Date: 12/05/15 09:45
• Summary: GENERAL: FPH: FPH Introduces New Range of Products for Airvo System
• Price Sensitive: No
• Download Document  3.52KB

					FPH
12/05/2015 09:45
GENERAL
NOT PRICE SENSITIVE
REL: 0945 HRS Fisher & Paykel Healthcare Corporation Limited

GENERAL: FPH: FPH Introduces New Range of Products for Airvo System

FISHER & PAYKEL HEALTHCARE INTRODUCES NEW RANGE OF PRODUCTS FOR AIRVO(TM)
NASAL HIGH FLOW SYSTEM
Auckland, New Zealand, 12 May 2015 - Fisher & Paykel Healthcare Corporation
Limited (NZSX:FPH, ASX:FPH) today announced the introduction of a range of
innovative new products for use with the AIRVO 2 system. These new products,
used in delivering nasal high flow therapy, include the Optiflow(TM)+ nasal
cannula range, AirSpiral(TM) tube and an uninterruptible power supply (UPS)
transport system for continuous therapy during transport within the hospital.

"The leading-edge technologies included in our new Optiflow+ nasal cannula
and AirSpiral tube originate from Fisher & Paykel Healthcare's dedication to
improve care and outcomes, giving clinicians confidence in the comfortable
delivery of nasal high flow therapy" said Lewis Gradon, Fisher & Paykel
Healthcare's Senior Vice President of Products and Technology. "More and more
clinicians around the world are choosing to use our AIRVO 2 nasal high flow
therapy system with Optiflow as an alternative to conventional low flow
oxygen therapy. The new technologies that we are announcing today have given
clinicians even more reason to make the change."

The new range of Optiflow+ nasal cannula improve comfort and stability and
feature soft contoured prongs and cheek pads that simplify eating, drinking
and communication compared to face masks. The unique dual connector fits all
F&P circuits and is compatible with both F&P AIRVO and F&P 850(TM) systems.
The new cannulas also include F&P's Evaqua(TM) technology, which reduces the
formation of condensate as the permeable membrane allows water to freely
diffuse through the walls of the tubing.

The new AirSpiral tube for AIRVO 2 utilises an advanced two-spiral design
which produces up to 96% less condensate than previous tube technology. Less
condensate means fewer therapy interruptions and, along with AirSpiral's
reduced size and weight, improved patient care.

The addition of an UPS to the AIRVO 2 system opens up a world of
possibilities for delivering nasal high flow "on the move" throughout
hospitals and long-term care facilities.

Continuous power means continuous therapy: during transport between emergency
rooms, intensive care units, general care areas and radiology departments, as
well as during rehabilitation or diagnostic procedures.

"The addition of the UPS to the AIRVO 2 means that patients can stay on the
same therapy and same equipment, simplifying patient care as well as reducing
workload and costs. We believe this will facilitate accelerated growth of
Optiflow nasal high flow therapy throughout the hospital, including in
general care areas and in the emergency department" concluded Mr Gradon.

The new Optiflow+ nasal cannula range, AirSpiral tube and UPS transport
system for AIRVO 2 are currently available in New Zealand, Australia, Canada
and in select European markets, with a global rollout planned throughout 2015
and early 2016.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer
of products and systems for use in respiratory care, acute care, surgery and
the treatment of obstructive sleep apnea. The company's products are sold in
over 120 countries worldwide. For more information about the company, visit
our website www.fphcare.com.
End CA:00264194 For:FPH    Type:GENERAL    Time:2015-05-12 09:45:36